A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies

Purpose To determine the maximum tolerated dose and duration of hepatic arterial infusion (HAI) gemcitabine in patients with unresectable hepatic metastases from colorectal cancer or primary hepatic malignancies.